Pharma manufacturing spent 90 years learning that producing correct outputs isn't the same as catching your own errors. AI has only learned the first.
News|Articles|September 16, 2015
PTSM: Pharmaceutical Technology Sourcing and Management
- PTSM: Pharmaceutical Technology Sourcing and Management-10-07-2015
- Volume 11
- Issue 10
FDA Issues Import Ban for Indian Drug Manufacturer
Author(s)Pharmaceutical Technology Editors
Polydrug Laboratories is issued a US import alert, following similar bans in Canada and Europe.
Advertisement
FDA has issued an import ban on Sept. 11, 2015 for products manufactured by Polydrug Laboratories at the company’s Ambernath Industrial Area manufacturing plant in Mumbai, India, due to problems with good manufacturing practices for human and animal drugs.
The company manufactures anti-hypertensive, anti-fungal, anti-microbial, and muscle relaxant drugs, and distributes products in Mexico, China, Korea, Russia,Taiwan, Singapore, and Ukraine, according to information posted on the
Source:
Articles in this issue
about 11 years ago
Cost Inhibits CMO Adoption of Single-Use Equipmentabout 11 years ago
Low Temperature Needed for Complex Drug Candidatesabout 11 years ago
FDA Plans Pilot Projects for Drug Supply Chain Security Actabout 11 years ago
Vetter Embarks on 300-Million Euro Manufacturing Expansionabout 11 years ago
Sterigenics International Adds Capacityabout 11 years ago
Tecnandina’s Ecuador Facility Receives ANVISA Certificationabout 11 years ago
Hovione Expands Drug Substance Manufacturingabout 11 years ago
Piramal Introduces Proof of Concept Service for Next Wave of ADC Growthabout 11 years ago
Patheon Unveils New Brand Identityabout 11 years ago
FDA Releases Guidance on Generic-Drug DevelopmentAdvertisement
Related to this article
Richard Jaenisch explains what FDA's real-world use case database means for CMC and quality teams navigating NAMs.
Boyang Wang, Immortal Dragons, explains how FDA’s Expedited IND Pilot and research partners could speed serial steps to first-in-human trials compared to China’s 818 Decree.
This article examines how modern automation platforms create the digital foundation required for Pharma 4.0 by integrating manufacturing systems, centralized data management, Industrial Internet of Things connectivity, electronic batch production records, and AI-driven analytics.
The FDA approves oral pritelivir for drug-resistant herpes sores in immunocompromised patients; what it means for antiviral development and manufacturing.
This week, drug formulation and manufacturing experts showcased their knowledge, and companies exhibited their products, at CPHI Milan.
FDA approves Teva’s Weltruza, a once-monthly subcutaneous olanzapine for schizophrenia whose copolymer depot eliminates post-injection monitoring.
Equivalence test using two one-sided tests are widely used for demonstrating the comparability of treatment effects in different research fields. The method described in the manuscript aims to use simulations in Microsoft Excel to compute power for 2 one-sided tests for two groups with unequal variances.
Advertisement
Advertisement
Trending on Pharmaceutical Technology
1
What the Olanzapine Depot Approval Means for CMC Teams
2
Pritelivir Shifts Resistant Herpes Care from Intravenous to Oral
3
Q&A: Patient-Centric Drug Development Should Start at Product Definition
4
PharmTech Weekly Roundup—Oct. 8, 2026: CPHI Highlights
5